tradingkey.logo

BRIEF-United Therapeutics Fully Enrolls Teton 1 Study Of Inhaled Treprostinil For Idiopathic Pulmonary Fibrosis

ReutersFeb 4, 2025 12:28 PM

- United Therapeutics Corp UTHR.O:

  • UNITED THERAPEUTICS CORPORATION ANNOUNCES FULL ENROLLMENT OF THE TETON 1 STUDY OF INHALED TREPROSTINIL FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

  • UNITED THERAPEUTICS CORP - TOP LINE DATA EXPECTED IN FIRST HALF OF 2026

Source text: ID:nBw8RKwQ5a

Further company coverage: UTHR.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI